VNDA

Vanda Pharmaceuticals (VNDA)

About Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Details

Daily high
$4.80
Daily low
$4.65
Price at open
$4.80
52 Week High
$6.75
52 Week Low
$3.87
Market cap
278.2M
Dividend yield
0.00%
Volume
667,483
Avg. volume
584,525
P/E ratio
-14.68

Vanda Pharmaceuticals News

Details

Daily high
$4.80
Daily low
$4.65
Price at open
$4.80
52 Week High
$6.75
52 Week Low
$3.87
Market cap
278.2M
Dividend yield
0.00%
Volume
667,483
Avg. volume
584,525
P/E ratio
-14.68